Merck Defends Inaction on Vioxx VIGOR Data, Cites Naproxen Heart Benefit
This article was originally published in The Tan Sheet
Executive Summary
Merck continues to support the cardioprotective effect of the non-steroidal anti-inflammatory drug naproxen
You may also be interested in...
Merck Legal Defense May Raise Cardioprotective Profile Of Naproxen
Liability related to Merck's Vioxx withdrawal may define the future safety profile of naproxen
Celebrex Cardiovascular Safety Trial Will Allow Acetaminophen Use
Pfizer believes that allowing patients to take non-NSAID pain relievers, such as acetaminophen, in a trial evaluating the cardiovascular risk profile of Celebrex (celecoxib) will make a long-term placebo-controlled study in the arthritis population feasible
Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers
OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)